Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a monthly compilation of research articles funded by AHRQ or authored by AHRQ researchers and recently published in journals or newsletters.
Results1 to 2 of 2 Research Studies Displayed
Glenn BA, Nonzee NJ, Tieu L
Human papillomavirus (HPV) vaccination in the transition between adolescence and adulthood.
This study looked at the barriers to human papillomavirus (HPV) vaccination among young adults receiving care at the student health center of a large public university. The authors conducted semi-structured interviews (n=27) and four focus groups with undergraduate and graduate students (n=18) and semi-structured interviews with 6 health care providers. The interviews and focus groups explored perceived risk of HPV infection, benefits of the HPV vaccine, and motivations for and barriers to HPV vaccination. Many students cited their parents’ views and recommendations from their medical providers as influential on their decision-making process. Cervical cancer prevention was considered the main benefit of the HPV vaccine and sexual activity was a risk factor for HPV infection. Students often lacked knowledge about the vaccine’s benefit for males. Safety and side effects of the vaccine perceived as new were also cited. Providers’ vaccine recommendations were impacted by health system factors including clinical infrastructure, office visit priorities, and processes for recommending and documentation vaccination. Providers suggested various promotion strategies including improving the timing and messaging of outreach efforts on campus and bolstering clinical infrastructure.
Citation: Glenn BA, Nonzee NJ, Tieu L . Human papillomavirus (HPV) vaccination in the transition between adolescence and adulthood. Vaccine 2021 Jun 8;39(25):3435-44. doi: 10.1016/j.vaccine.2021.04.019..
Keywords: Young Adults, Sexual Health, Infectious Diseases, Vaccination, Prevention, Cancer: Cervical Cancer, Cancer, Women
Asti L, Hopley C, Avelis C
The potential clinical and economic value of a human papillomavirus primary screening test that additionally identifies genotypes 31, 45, 51, and 52 individually.
This study looked at the potential clinical and economic value of a human papillomavirus (HPV) primary screening test that additionally identified genotypes 31,45,51, and 52 along with genotypes 16 and 18. The authors developed a Markov model of the HPV disease course and evaluated the clinical and economic value of HPV primary screening with Onclarity. Currently HPV primary screening results in 25,194 invasive procedures and 48 invasive cervical cancer (ICC) cases per 100,000 women. Screening with extended genotyping and later screening women with certain genotypes averted 903 to 3163 invasive procedures and results in 0 to 3 more ICC cases compared with current primary screening tests. Extended genotyping was cost effective when costing $75 and cost saving when costing $43. When the probabilities of disease progression increased 2-4 times, it was not cost-effective because it resulted in more ICC cases and accrued fewer quality-adjusted life-years.
Citation: Asti L, Hopley C, Avelis C . The potential clinical and economic value of a human papillomavirus primary screening test that additionally identifies genotypes 31, 45, 51, and 52 individually. Sex Transm Dis 2021 May;48(5):370-80. doi: 10.1097/olq.0000000000001327.
Keywords: Sexual Health, Infectious Diseases, Screening, Diagnostic Safety and Quality, Genetics, Cancer: Cervical Cancer, Cancer, Women